MELK (maternal embryonic leucine zipper kinase) is a serine/threonine kinase belonging to the snf1/AMPK family of protein.
Synonyms: Anti-Maternal embryonic leucine zipper kinase; Anti-Protein kinase PK38; Anti-hMELK; Anti-hPK38
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: MELK (maternal embryonic leucine zipper kinase) is involved in several processes such as preimplantation processes, cell cycle regulation, cell proliferation, apoptosis, hematopoiesis, oncogenesis, and emryonic growth. It plays a key role in the spliceosome assembly. It directly interacts with the nuclear protein during the cell cycle-regulated control of pre-mRNA splicing. It has been suggested that MELK plays an important role in cell cycle progression, which indicates its prognostic and therapeutic importance in prostate cancer.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC